Fractional Laser in Combination With UVB Therapy in Vitiligo Patients
Status:
Withdrawn
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Rationale: Vitiligo is a common skin disorder that can impair a patient's quality of life.
Many depigmented lesions in vitiligo patients remain therapy resistant for medical treatment.
Therefore new therapeutic options in these patients are necessary. Currently, dermabrasion by
conventional or fractional laser therapy in combination with NB-UVB therapy and steroids
appears to be effective in therapy resistant areas. However, little literature on this
combination is available.
Objectives: To assess the efficacy and patient safety of (1)fractional CO2-laser treatment in
combination with NB- UVB,(2) fractional CO2-laser treatment in combination with NB- UVB and
topical corticosteroids versus NB-UVB treatment alone(3) Study design: Prospective observer
blinded randomised intra-patient controlled study.
Study population: 23 patients ≥ 18 years with non segmental vitiligo who receive NB-UVB
treatment at the Netherlands Institute for Pigment Disorders (SNIP) at the Academic Medical
Centre University of Amsterdam. We will include patients with 3 depigmented lesions that are
resistant to NB- UVB treatment after 3 to 6 months.
Methods: Three NB-UVB resistant depigmented regions on the trunk or extremities will be
randomly allocated to;(1) NB-UVB treatment in combination with fractional CO2 laser abrasion,
or (2) NB-UVB treatment in combination with fractional CO2 laser abrasion and topical
steroids, or (3) NB-UVB treatment alone. NB-UVB treatment and topical steroids will be given
according to the standard treatment protocol of the SNIP and continued for at least 6 months.
Two and 6 months after the laser treatment, the percentage of repigmentation of the lesions
will be assessed.